Aurobindo's Molnaflu for Covid treatment

Hyderabad: Aurobindo Pharma Limited has made its brand of molnupiravir- Molnaflu available widely in India. It is for treatment of adult patients with Covid-19, with Sp02 >93 per cent and who have high risk of progression of the disease including hospitalisation or death.

This is the first oral antiviral approved by India, the UK agency and also by US Foods and Drugs Administration. Japan's Ministry of Health, Labor and Welfare (MHLW) granted special approval for emergency in Japan for Molnupiravir for infectious disease caused by SARS-CoV-2. Aurobindo had signed a bi-lateral agreement with Merck Sharpe Dohme(MSD), Singapore, to manufacture and supply Molnupiravir to over 100 low and middle-income countries (LMIC).

K Nithyananda Reddy, Vice Chairman and Managing Director, Aurobindo said: "We are delighted with the timely permission from DCGI, this will enable us to help battle the pandemic with effective and high-quality pharmaceutical products. The product advances our mission of being committed to healthier life".

City based Aurobindo Pharma Limited is an integrated global pharmaceutical company. The Company develops, manufactures, and commercializes a wide range of generic, branded specialty pharmaceuticals and active pharmaceutical ingredients globally in over 155 countries.